Fermelanta - About the company
Fermelanta is a series A company based in Nonoichi (Japan), founded in 2022 by Shogo Fukizaki and Hiromichi Minami. It operates as a Provider of a biotech company that uses microbial fermentation to produce plant-based chemicals, including secondary metabolites for use in medicines, cosmetics, and health foods. Fermelanta has raised $15M in funding from investors like Plug and Play Tech Center, Beyond Next Ventures and Angel Bridge. The company has 532 active competitors, including 182 funded and 89 that have exited. Its top competitors include companies like Ginkgo Bioworks, Syngenta and Spark Therapeutics.
Company Details
Provider of a biotech company that uses microbial fermentation to produce plant-based chemicals, including secondary metabolites for use in medicines, cosmetics, and health foods.
- Website
- fermelanta.com
- Email ID
- *****@fermelanta.com
Key Metrics
Founded Year
2022
Location
Nonoichi, Japan
Stage
Series A
Total Funding
$15M in 3 rounds
Latest Funding Round
Investors
Ranked
41st among 532 active competitors
Employee Count
15 as on Jun 30, 2026
Similar Companies
Sign up to download Fermelanta's company profile
Fermelanta's funding and investors
Fermelanta has raised a total funding of $15M over 3 rounds. Its first funding round was on Jun 14, 2023. Its latest funding round was a Grant (prize money) round on Sep 01, 2025 for $*****. 1 investor participated in its latest round. Fermelanta has 11 institutional investors.
Here is the list of recent funding rounds of Fermelanta:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 01, 2025 | 5690873 | Grant (prize money) | 6853654 | 1594978 | 6907545 | 3048314 |
Aug 29, 2025 | 7242269 | Series A | 3619719 | 4201587 | 8772238 | |
Jun 14, 2023 | 6837915 | Seed | 1862583 | 8170070 | 4199104 |
Access funding benchmarks and valuations. Sign up today!View details of Fermelanta's funding rounds and investors
Fermelanta's founders and board of directors
Founder? Claim ProfileThe founders of Fermelanta are Shogo Fukizaki and Hiromichi Minami. Shogo Fukizaki is the CEO of Fermelanta.
Here are the details of Fermelanta's key team members:
- Shogo Fukizaki: Co-Founder & CEO of Fermelanta.
- Hiromichi Minami: Co-Founder & CSO of Fermelanta. Contact Info: 1 email address
View details of Fermelanta's Founder profiles and Board Members
Fermelanta's employee count trend
Fermelanta has 15 employees as of Jun 26. Here is Fermelanta's employee count trend over the years:
Uncover Fermelanta's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Fermelanta's Competitors and alternates
Top competitors of Fermelanta include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Here is the list of Top 10 competitors of Fermelanta, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Ginkgo Bioworks 2008, Boston (United States), Public | Autonomous labs for biotechnology, empowering scientists to design the living world | $796M | 81/100 | |
2nd |  Syngenta 2000, Basel (Switzerland), Acquired | Developer of technologies and sustainable farming practices for farmers | - | 75/100 | |
3rd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
4th |  Twist Bioscience 2013, San Francisco (United States), Public | Developer of a semiconductor-based DNA synthesis platform | $321M | 72/100 | |
5th |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 70/100 | |
6th | LanzaTech 2005, Skokie (United States), Public | Developer of technology converting carbon-rich gases into fuels and chemicals | $869M | 70/100 | |
7th | _1560516450043.png?devicePixelRatio=2&height=30&width=30){kind=logo} Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
8th | Codexis 2002, Redwood City (United States), Public | Developer of high-performance enzymes for drug discovery | $111M | 68/100 | |
9th |  AskBio 2001, Durham (United States), Acquired | Developer of AAV technologies for treating genetic and complex disorders | $235M | 68/100 | |
10th | Company focused on developing alternative animal products through microbial precision fermentation | $14.5M | 67/100 | ||
41st | Fermelanta 2022, Nonoichi (Japan), Series A | Provider of a biotech company that uses microbial fermentation to produce plant-based chemicals, including secondary metabolites for use in medicines, cosmetics, and health foods | $15M | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Fermelanta's competitors? Click here to see the top ones
Fermelanta's Investments and acquisitions
Fermelanta has made no investments or acquisitions yet.
Reports related to Fermelanta
Here is the latest report on Fermelanta's sector:
News related to Fermelanta
Media has covered Fermelanta for a total of 3 events in the last 1 year.
•
•
•
Fermelanta raises 2 billion yen in Series A round for microbial fermentation productionStartup Log•Aug 29, 2025•Norinchukin Capital, Fermelanta, Hokkoku Financial Holdings, Angel Bridge and 8 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Fermelanta
Explore our recently published companies
- JTorres Construction - Conyers based, Unfunded company
- Wonderland Bank - Thailand based, Unfunded company
- Digital Cut - Point Cook based, 2018 founded, Unfunded company
- Decapolis Press Media & Events - United States based, 2022 founded, Unfunded company
- Livin Luxuries - Unfunded company
- Fakir Chand College - India based, Unfunded company
